Literature DB >> 12876896

The immune reconstitution inflammatory syndrome.

Samuel A Shelburne1, Richard J Hamill.   

Abstract

The use of highly active antiretroviral therapy (HAART) has led to a substantial decrease in the frequency of opportunistic infections among HIV-infected individuals, along with a significant reduction in their mortality rate. However, a subgroup of HAART-treated patients will exhibit paradoxical deterioration in their clinical status, despite satisfactory control of viral replication and improvements in CD4 lymphocyte counts. This clinical deterioration, known as the immune restoration syndrome or immune reconstitution inflammatory syndrome (IRIS), is a result of an exuberant inflammatory response towards previously diagnosed or incubating opportunistic pathogens, as well as responses towards other as yet undefined antigens. A variety of manifestations of IRIS have been described, most prominently including Mycobacterium avium complex lymphadenitis, paradoxical exacerbations of pulmonary and CNS Mycobacterium tuberculosis infection, paradoxical exacerbations of Cryptococcus neoformans meningitis and cytomegalovirus uveitis. Treatment for this disorder includes continuation of primary therapy against the offending pathogen in order to decrease the antigenic load, continuation of effective HAART, and judicious use of anti-inflammatory agents. Although the clinical manifestations of IRIS are sometimes dramatic, and result in substantial morbidity, the fact that these patients are capable of generating an inflammatory response allows many of them to ultimately discontinue secondary prophylaxis for the offending pathogen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876896

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  56 in total

Review 1.  Multiple sclerosis-like illness in a HIV-1 patient.

Authors:  Eduardo Durán; Juan Gálvez; Giorgio Patrignani; Guillermo Izquierdo
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 3.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

4.  A case for treating high hepatitis B DNA levels before starting HIV therapy.

Authors:  Jason V Baker; David R Boulware; Paul R Bohjanen
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

5.  Leprosy after starting antiretroviral treatment.

Authors:  Stephen D Lawn; Diana N J Lockwood
Journal:  BMJ       Date:  2007-02-03

6.  CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice.

Authors:  Steve D Swain; Nicole N Meissner; Allen G Harmsen
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

7.  [Introduction to the topic: immune reconstitution syndrome - relevance for the rheumatologist].

Authors:  E Märker-Hermann
Journal:  Z Rheumatol       Date:  2008-07       Impact factor: 1.372

8.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

9.  HIV-M. leprae interaction: can HAART modify the course of leprosy?

Authors:  Euzenir Nunes Sarno; Ximena Illarramendi; José A Costa Nery; Anna M Sales; Maria C Gutierrez-Galhardo; Maria L Fernandes Penna; Elizabeth Pereira Sampaio; Gilla Kaplan
Journal:  Public Health Rep       Date:  2008 Mar-Apr       Impact factor: 2.792

10.  Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Authors:  Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.